

February 14, 2023

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroze Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	---

Dear Sir/Madam,

Sub : Classification of US FDA Inspection at our Unit IX– Reg.,
Ref : Our Letters dated May 17, 2019 & November 19, 2022

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to our above referred letter, this is to inform you that:

As per the information available on the United States Food and Drug Administration website, the Company's Unit - IX, an API intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana, which was inspected by the United States Food and Drug Administration from November 10 to November 18, 2022, has now been classified as Voluntary Action Indicated (VAI).

We will keep the stock exchanges further informed if there is any material information relating to the above in the future.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com